COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB VERSUS CETUXIMAB IN FIRST-LINE TREATMENT FOR METASTATIC COLORECTAL CANCER IN KRAS WILD-TYPE PATIENTS IN THE SUPPLEMENTARY HEALTH CARE SYSTEM IN BRAZIL

被引：1
|
作者：
Tsuchiya, C. T. [1 ]
Kim, H. S. J. [1 ]
Maximo, M. F. M. [1 ]
Ramos, L. A. [1 ]
机构：
[1] Roche Brazil, Sao Paulo, Brazil
来源：
VALUE IN HEALTH | 2014年 / 17卷 / 07期
关键词：
D O I：
10.1016/j.jval.2014.08.2311
中图分类号：
F [经济];
学科分类号：
02 ;
摘要：
PCN152
引用
收藏
页码：A641 / A641
页数：1
相关论文
共 50 条
  • [1] COST-MINIMIZATION ANALYSIS OF BEVACIZUMAB COMPARED TO CETUXIMAB AND PANITUMUMAB IN FIRST-LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER IN FRANCE
    Gherardi, A.
    Masia, C.
    Plommet, N.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A738
  • [2] COST-MINIMIZATION ANALYSIS OF PANITUMUMAB COMPARED WITH CETUXIMAB IN THE FIRST-LINE TREATMENT OF WILD-TYPE RAS METASTATIC COLORECTAL CANCER PATIENTS IN BRAZIL
    dos Santos, R. F.
    Riveros, B. S.
    Nita, M. E.
    Pedro, G. O.
    VALUE IN HEALTH, 2016, 19 (07) : A738 - A739
  • [3] Cost-minimization analysis of panitumumab compared with cetuximab for first-line treatment of patients with wild-type RAS metastatic colorectal cancer
    Graham, Christopher N.
    Hechmati, Guy
    Fakih, Marwan G.
    Knox, Hediyyih N.
    Maglinte, Gregory A.
    Hjelmgren, Jonas
    Barber, Beth
    Schwartzberg, Lee S.
    JOURNAL OF MEDICAL ECONOMICS, 2015, 18 (08) : 619 - 628
  • [4] Cost-minimization analysis of biweekly dosing of cetuximab and FOLFIRI compared with panitumumab and FOLFOX for first-line treatment of patients with KRAS wild-type metastatic colorectal cancer in the United States
    Gathirua-Mwangi, Wambui Grace
    Sethi, Harsheen
    Afable, Manuel Geroy
    Bhattacharyya, Devarshi
    Khan, Taha
    JOURNAL OF MEDICAL ECONOMICS, 2021, 24 (01) : 1164 - 1172
  • [5] COST-EFFECTIVENESS OF CETUXIMAB AND BEVACIZUMAB IN THE FIRST-LINE TREATMENT OF METASTATIC COLORECTAL CANCER (MCRC) FOR PATIENTS WITH KRAS WILD-TYPE TUMOURS IN THE UNITED KINGDOM
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I
    VALUE IN HEALTH, 2011, 14 (07) : A446 - A447
  • [6] Cost-Effectiveness of Cetuximab and Bevacizumab in the First-Line Treatment of Metastatic Colorectal Cancer (mCRC) for Patients With KRas Wild-Type Tumours in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    EUROPEAN JOURNAL OF CANCER, 2011, 47 : S264 - S264
  • [7] CANADIAN ECONOMIC ANALYSIS OF BEVACIZUMAB, CETUXIMAB, AND PANITUMUMAB IN THE FIRST LINE TREATMENT OF KRAS WILD-TYPE METASTATIC COLORECTAL CANCER (MCRC)
    Lawrence, D.
    Maschio, M.
    Yunger, S.
    Easaw, J.
    Aucoin, N.
    Weinstein, M.
    ANNALS OF ONCOLOGY, 2012, 23 : 202 - 202
  • [8] Comparison of cetuximab and bevacizumab as first-line treatment in KRAS wild type advanced colorectal cancer patients: a retrospective analysis
    Zhang, Q.
    Leung, R.
    Wong, H.
    Chiu, J.
    Chu, K. W.
    Poon, J.
    Epstein, R. J.
    Kwong, Y. L.
    Yau, T.
    EUROPEAN JOURNAL OF CANCER, 2014, 50 : S12 - S12
  • [9] Cost-effectiveness of cetuximab, bevacizumab, and panitumumab in first-line treatment of metastatic colorectal cancer (mCRC) for patients with KRAS wild-type (wt) tumors in the United Kingdom
    Samyshkin, Y.
    Hertel, N.
    Griebsch, I.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [10] First-line cetuximab-based chemotherapies for patients with advanced or metastatic KRAS wild-type colorectal cancer
    Ohta, Katsuya
    Ikenaga, Masakazu
    Uemura, Mamoru
    Sakata, Kazuya
    Nishimura, Junichi
    Hata, Taishi
    Matsuda, Chu
    Mizushima, Tsunekazu
    Doki, Yuichiro
    Mori, Masaki
    JOURNAL OF GASTROENTEROLOGY AND HEPATOLOGY, 2016, 31 : 216 - 216
12345